Oncology CME

  • FEATURED
    FREE GIFT CARD

    BoardVitals Hematology and Oncology CME Pro Plus w/ Bonus $3,000 Amazon or Visa Prepaid Card

    Complete your CME and MOC Requirements Online with the BoardVitals Online CME + MOC Hematology/Oncology Self-Assessment Activity with up to a bonus $3,000 Amazon or Visa Prepaid Card. Answer board-style questions and cases related to your specialty and earn credits fast!

    Key features of BoardVitals Online CME + MOC Self-Assessment Activity include:

    • Thousands of board-style questions and cases with evidence based explanations for review
    • Aligned with the MOC / Recertification exam content for your specialty board
    • Answer questions to earn credits and correct wrong answers as you go
    • Earn up to 100 AMA PRA Category 1 CreditsTM and MOC credits (varies by specialty)
    • Up to 24-month access + a bonus $3,000 Amazon or Visa Prepaid Card (your choice.)

    Target Audience: Physicians specializing in Hematology or Oncology.

    See full details chevron_right
    • Cost: Varies
    • Credit hours: 27
    • CME credits awarded by: University of Nebraska Medical Center
    • Format: On-Demand Online
    • Material last updated: Continuously Updated
  • FEATURED
    FREE GIFT CARD

    MDCalc CME With Free $3,000 Gift Card

    Maximize your CME allowance with MDCalc and get up to a $3,000 bonus gift card of your choice. Earn AMA PRA Category 1 CreditsTM for clinical content on 150+ calculators across multiple medical specialties. Easily earn and redeem CME at the point-of-care, online on our website or mobile app. Over 1 million medical professionals use MDCalc’s 550+ tools daily to support clinical decision making at the bedside.

    See full details chevron_right
    • Cost: Varies
    • Credit hours: Unlimited
    • CME credits awarded by: EBMedicine
    • Format: On-Demand Online
    • Material last updated: Continuously Updated
  • FEATURED

    BoardVitals Hematology and Oncology CME Board Review

    The BoardVitals Hematology and Oncology CME Review offers clinicians 27 AMA PRA Category 1 CreditsTM, 27 ABIM MOC points, and over 500 Hematology and Oncology board review questions. The questions cover key topics including Breast Cancer, Gynecologic Cancer, and Transfusion Medicine. This question bank will assist clinicians with Hematology and Oncology certification and recertification.

    The BoardVitals Hematology and Oncology CME Review also features:

    • Quick and Convenient CME
    • Computer, phone, and tablet access
    • Constantly updated up-to-date questions
    • Questions that are targeted specifically to the exam
    • Online CME tracker
    • 100% Pass Guarantee
    • Statistical comparison to other Hematology and Oncology test-takers (Nationally)

     

    After completing this activity, you should be able to:

    • Make a diagnosis
    • Order and interpret results
    • Assess risk, determine prognosis, and apply principles from epidemiologic studies
    • Describe the underlying pathophysiology of disease and basic science knowledge

     

    Target Audience: Hematologists and Oncologists

    See full details chevron_right
    • Cost: $599
    • Credit hours: 27
    • CME credits awarded by: BoardVitals
    • Format: On-Demand Online
    • Material last updated: Continuously Updated
  • StatPearls Unlimited Physician MD/DO/PA CME

    Stay on top of your game with the StatPearls Physician Unlimited CME programs. With 6,046 activities, StatPearls is the largest CME provider in the world. These Pub-Med Indexed articles are categorized into 162 specialty areas which lets you better access activities that will make the biggest impact on your practice. One subscription allows access to all the activities, including all state-requirements.

    Pricing Options

    • 6 Month subscription: All 6,339 CME Activities $249 per 6 months
    • Annual subscription: All 6,339 CME Activities $349 per 1 year
    • Lifetime: All 6,339 CME Activities + Access to Board Reviews Forever $1999
    See full details chevron_right
    • Cost: Varies
    • CME credits awarded by: ETSU
    • Format: On Demand Online & Board Reviews
  • Oakstone CME Molecular Diagnostics: Cancer Diagnosis and Patient Management

    Learn Now: Advances in Molecular Diagnostics

    In Molecular Diagnostics: Cancer Diagnosis and Patient Management, experts in the field review current concepts and up-to-date techniques, delving into the appropriate use of molecular assays for different tumor types to inform diagnosis, prognosis, or treatment using evidence-based guidelines.

    Lectures in this online CME course illustrate common diagnostic pitfalls, with additional focus on variant interpretation and the complexity of billing for molecular tests. It’s continuing medical education that will help you to:

    • Develop appropriate tissue-handling protocols
    • Evaluate cytogenetic and molecular techniques, including next generation sequencing assays
    • Recognize cost-effective, time-sensitive approaches to molecular studies, including cell free DNA testing
    • Determine the process of clinical interpretation of genetic variation
    • Analyze costs and potential sources of revenue for molecular diagnostics programs
    • Consider essential and emerging biomarkers in common adult and pediatric solid and liquid tumors
    See full details chevron_right
    • Cost: $895
    • Credit hours: 18
    • CME credits awarded by: Oakstone Publishing, LLC.
    • Material last updated: October 30, 2021
    • Expiration of CME credit: January 31, 2024
  • 15% OFF W/ CODE: CME15

    Oakstone CME Brigham and Dana-Farber Board Review in Oncology

    Key Topics in Oncology CME

    The Brigham and Dana-Farber Board Review in Oncology is an online CME course designed to update knowledge and improve management strategies. Case-based presentations from a distinguished faculty of experts will help enhance patient care while you prep for the board exam with continuing medical education that helps you to:

    • Apply recommended oncology guidelines in clinical practice
    • Perform differential diagnosis of complex oncologic disorders
    • Identify and apply current therapeutic options for oncologic disorders
    • Evaluate and interpret up-to-date literature relevant to oncology
    • Illustrate knowledge of pathophysiology as it applies to management of oncology disorders
    • Apply knowledge gained to the ABIM certification/recertification oncology examinations

    Learning Objectives

    At the conclusion of this activity, the participant will be able to:

    • Apply current/recommended Oncology guidelines in clinical practice
    • Perform differential diagnosis of complex clinical presentations related to Oncologic disorders
    • Identify/apply current therapeutic options for specific Oncologic disorders
    • Review and interpret up-to-date literature relevant to clinical practice in Oncology
    • Demonstrate knowledge of pathophysiology as it applies to management of Oncology disorders
    • Apply knowledge gained to the ABIM Certification/Recertification Medical Oncology examinations

    Intended Audience

    The activity was planned for fellows/trainees, practicing Oncology specialists (MDs), and other professional affiliates (internists with an interest in Oncology) who are preparing to take ABIM Board Review or Recertification Examinations, or who seek CME activities to improve patient care in the areas of Oncology Medicine.

    See full details chevron_right
    • Cost: $1295
    • Credit hours: 25.25
    • CME credits awarded by: Oakstone Publishing, LLC
    • Format: On-Demand Online, Online Video, Online Audio, Audio CD
    • Material last updated: April 15, 2020
    • Expiration of CME credit: April 15, 2023
  • FREE

    Update on Therapeutic Advances in T-Cell Lymphoma

    Join Steven M. Horwitz, MD, Member and Attending Physician at Memorial Sloan Kettering Cancer Center, as he discusses guideline recommendations for differential diagnosis of TCL, novel treatment strategies, and best practices for managing side effects in this case-based live webinar series! Register today!

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: i3 Health
    • Format: Webinar
  • FREE

    Virtual Tumor Board: Diagnosis and Management of Myelodysplastic Syndromes

    In this virtual tumor board, David P. Steensma, MD, FACP, Reza Nejati, MD, and Ilene Galinsky, BSN, MSN, ANP-C, discuss patient and tumor characteristics that inform personalized care plans, risk stratification, and supportive care strategies for patients with MDS.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: i3 Health in partnership with Anaplastic Anemia & Myelodysplastic Syndromes International Foundation
    • Format: Online, On Demand
  • FREE

    Treating Oncology Patients During COVID-19

    Activity Description / Statement of Need: The COVID-19 pandemic has led to unprecedented changes in health care delivery worldwide, affecting the way that nearly every medical specialty can safely practice. As with other fields of medicine, oncology has its own challenges in navigating the pandemic. Based on pre-pandemic estimates, 1.8 million new cancer diagnoses would be expected in 2020, equating to approximately 5,000 new cancer diagnoses per day. Evidence thus far suggests that COVID-19 is associated with significantly more complications and a higher risk of death in patients with cancer or with a history of cancer. Furthermore, patients with cancer have also been shown to have a higher COVID-19 infection rate than the general population, suggesting increased susceptibility, potentially due to immunosuppression, comorbidities, or poor health status related to cancer or its treatment. Based on these data, oncology specialists are said to be fighting “a war on two fronts” by balancing the risks of COVID-19 transmission and acquisition with the risks of delayed cancer diagnosis and treatment. This represents an unmet need among oncology practitioners as they navigate this new health care landscape.

    Target Audience:

    Healthcare professionals, including medical oncologists; radiation oncologists; surgical oncologists; surgeons; radiologists; nuclear medicine specialists; nurse practitioners and physician assistants who practice in oncology; and other healthcare providers who manage cancer.

    By the end of the session the participant will be able to:

    • Recall the symptoms of COVID-19 infection and best practices for screening patients, health care providers, and staff in the oncology setting.
    • Develop a plan to provide oncology care in the setting of the COVID-19 pandemic.
    • Describe the risks of delaying cancer diagnosis and treatment against the risk of COVID-19 exposure and infection.
    • See full details chevron_right
    • Cost: Free
    • Credit hours: .75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 09/22/2020
    • Expiration of CME credit: 09/22/2022
  • FREE

    Addressing skeletal-related events in prostate cancer

    Each year, an estimated 170,000 cases of prostate cancer are diagnosed. Although early prostate cancer may be cured with surgery or radiation therapy, more than 50% of men will experience recurrence after definitive treatment. The use of androgen deprivation therapy (ADT) for intermediate-risk, high-risk, and recurrent prostate cancer has greatly increased in the last 15 years, extending 10-year survival by nearly 25% compared with observation alone. New treatment options for advanced prostate cancer have further improved survival and increased the number of patients living with non-metastatic and metastatic castration-resistant prostate cancer (nmCRPC and mCRPC). Despite the established improvements in survival associated with hormonal treatments, ADT has been associated with well-characterized negative effects on bone health. Indeed, bone metastases and subsequent skeletal-related events (SREs) are the primary driver of both morbidity and mortality among people with CRPC. In a study of 2234 men aged 65 years or older with a diagnosis of CRPC, 40% experienced SREs over a median follow-up of 10.6 months. Maintaining bone health in patients with CRPC requires routine monitoring and proactive management.

    Target Audience:

    The following healthcare professionals: urologists, medical and radiation oncologists, primary care physicians, nuclear medicine specialists and radiologists, and endocrinologists; physician assistants, nurse practitioners, and pharmacists who treat prostate cancer; and any other healthcare professionals who commonly care for patients with prostate cancer.

    By the end of the session the participant will be able to:

    • Recall the relative efficacy and safety of presently available agents used to for bone health and fracture prevention in patients with prostate cancer
    • Describe the identification and management of disease and intervention adverse effects on patients
    • Using details in a patient case, recommend an appropriate pharmacotherapeutic treatment plan for the purpose of preventing SREs in patients with prostate cancer
    See full details chevron_right
    • Cost: Free
    • Credit hours: .75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 07/31/2020
    • Expiration of CME credit: 07/31/2022